Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors;Behandlung der demenz bei parkinson-syndromen. Wirksamkeit von cholinesterasehemmern

Nervenarzt

Volumn 79, Issue 1, 2008, Pages 36-46

  Liepelt, I ^a   Maetzler, W ^a   Blaicher, H P ^b   Gasser, T ^a   Berg, D ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cholinesterase inhibitors; Dementia; Lewy body disease; Parkinsonian syndromes; Therapy

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PHYSOSTIGMINE; RIVASTIGMINE;

COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DAILY LIFE ACTIVITY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HEALTH BEHAVIOR; HUMAN; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; LEWY BODY DISEASE; PARKINSONIAN DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUPRANUCLEAR PALSY, PROGRESSIVE; TREATMENT OUTCOME;

EID: 38349186934     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2312-2     Document Type: Review

References (69)

1. Aarsland D, Andersen K, Larsen JP et al. (2001) Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 56: 730-736
2. Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 937-941
3. Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72: 708-712
4. Aarsland D, Perry R, Brown A et al. (2005) Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 58: 773-776
5. Albert ML, Feldman RG, Willis AL (1974) The 'subcortical dementia' of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37: 121-130
6. Ballard C, Piggott M, Johnson M et al. (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 48: 868-876
7. Beversdorf DQ, Warner JL, Davis RA et al. (2004) Donepezil in the treatment of dementia with lewy bodies. Am J Geriatr Psychiatry 12: 542-544
8. Birks J, Grimley EJ, Iakovidou V, Tsolaki M (2000) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 4: CD001191
9. Birks JS, Melzer D, Beppu, H (2000) Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev 4: CD001190
10. Blin J, Mazetti P, Mazoyer B et al. (1995) Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain 118: 1485-1495
11. Bohnen NI, Kaufer DI, Hendrickson R et al. (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 253: 242-247
12. Bohnen NI, Kaufer DI, Ivanco LS et al. (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60: 1745-1748
13. Braak H, Rub U, Jansen Steur EN et al. (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64: 1404-1410
14. Cordato NJ, Pantelis C, Halliday GM et al. (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125: 789-800
15. Emre M (2003) Dementia associated with Parkinson's disease. Lancet Neurol 2: 229-237
16. Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518
17. Fabbrini G, Barbanti P, Bonifati V et al. (2001) Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 103: 123-125
18. Frattali CM, Grafman J, Patronas N et al. (2000) Language disturbances in corticobasal degeneration. Neurology 54: 990-992
19. Giladi N, Shabtai H, Gurevich T et al. (2003) Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 108: 368-373
20. Gilman S, Koeppe RA, Little R et al. (2005) Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol [Suppl 1] 191: S95-S103
21. Grace J, Daniel S, Stevens T et al. (2001) Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 13: 199-205
22. Grace JB, Walker MP, McKeith IG (2000) A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 15: 1028-1033
23. Graham NL, Bak TH, Hodges JR (2003) Corticobasal degeneration as a cognitive disorder. Mov Disord 18: 1224-1232
24. Groschel K, Hauser TK, Luft A et al. (2004) Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 21: 714-724
25. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102: 355-363
26. Higginson CI, King DS, Levine D et al. (2003) The relationship between executive function and verbal memory in Parkinson's disease. Brain Cogn 52: 343-352
27. Hilker R, Thomas AV, Klein JC et al. (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65: 1716-1722
28. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 61: 324-325
29. Janvin CC, Aarsland D, Larsen JP (2005) Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 18: 149-154
30. Jellinger K, Danielczyk W, Fischer P, Gabriel E (1990) Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 95: 239-258
31. Jellinger KA (2006) The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci 248(1-2): 167-172
32. Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol (Berl) 112(3): 253-260
33. Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109: 329-339
34. Kertzman C, Robinson DL, Litvan I (1990) Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 47: 1346-1350
35. Kompoliti K, Goetz CG, Boeve BF et al. (1998) Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55: 957-961
36. Le Rhun E, Richard F, Pasquier F (2005) Natural history of primary progressive aphasia. Neurology 65: 887-891
37. Leroi I, Brandt J, Reich SG et al. (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19: 1-8
38. Litvan I, Cummings JL, Mega M (1998) Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 65: 717-721
39. Litvan I, Gomez C, Atack JR et al. (1989) Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 26: 404-407
40. Litvan I, Phipps M, Pharr VL et al. (2001) Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57: 467-473
41. Loy C, Schneider L (2004) Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 4: CD001747
42. Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 4: CD001747
43. McKeith I, Del Ser T, Spano P et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036
44. McKeith IG (2002) Dementia with Lewy bodies. Br J Psychiatry 180: 144-147
45. McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 65: 1863-1872
46. McKeith IG, Grace JB, Walker Z et al. (2000) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15: 387-392
47. Minett TS, Thomas A, Wilkinson LM et al. (2003) What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 988-993
48. Miyasaki JM, Shannon K, Voon V et al. (2006) Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (Published online)
49. Papapetropoulos S, Gonzalez J, Mash DC (2005) Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 54: 1-9
50. Pillon B, Czernecki V, Dubois B (2003) Dopamine and cognitive function. Curr Opin Neurol [Suppl 2] 16: 17-22
51. Poewe W, Wolters E, Emre M et al. (2005) Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. Mov Disord 21(4): 456-461
52. Putt ME, Ravina B (2002) Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease. Control Clin Trials 23: 111-126
53. Querfurth HW, Allam GJ, Geffroy MA et al. (2000) Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord 11: 314-321
54. Quinn NP (2005) How to diagnose multiple system atrophy. Mov Disord [Suppl 12] 20: S5-S10
55. Ravina B, Putt M, Siderowf A et al. (2005) Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76: 934-939
56. Reading PJ, Luce AK, McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171-1174
57. Samuel W, Caligiuri M, Galasko D et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794-802
58. Schneider JA, Watts RL, Gearing M et al. (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48: 959-969
59. Shinotoh H, Namba H, Yamaguchi M et al. (2001) In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy. Adv Neurol 86: 249-255
60. Tiraboschi P, Hansen LA, Alford M et al. (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411
61. Warren NM, Piggott MA, Perry EK, Burn DJ (2005) Cholinergic systems in progressive supranuclear palsy. Brain 128: 239-249
62. Watts RL, Mirra SS, Richardson EP Jr (eds) (1994) Corticobasal ganglionic degeneration. Vol. 3, Butterworth-Heinemann, Oxford, pp 282-299
63. Werber EA, Rabey JM (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108: 1319-1325
64. Wesnes KA, McKeith I, Edgar C et al. (2005) Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65: 1654-1656
65. Wesnes KA, McKeith IG, Ferrara R et al. (2002) Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13: 183-192
66. Wild R, Pettit T, Burns A (2003) Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 3: CD003672
67. Zgaljardic DJ, Foldi NS, Borod JC (2004) Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transm 111: 1287-1301
68. Thomas AJ, Burn DJ, Rowan EN et al. (2005) A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20: 938-944
69. Edwards KR, Hershey L, Wray L et al. (2004) Efficacy and safty of galantamine in patients with dementia with Lewy bodies: a 12 week interim analysis. Dement Geriatr Cog Disord 17 [Suppl 1]: 40-48